Comparison of first-line immuno-oncology combinations with molecular targeted therapy in patients with advanced renal cell carcinoma undergoing hemodialysis: a real-world multicenter retrospective study
{{output}}
Background: Patients with advanced renal cell carcinoma (RCC) undergoing hemodialysis are often excluded from clinical trials. We aimed to evaluate real-world outcomes of first-line molecular targeted therapy (MTT) and immuno-onc... ...
